Could early CMV and TB drugs save HIV-Positive babies with pneumonia?
NCT ID NCT03915366
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether giving HIV-infected infants with severe pneumonia early treatment for cytomegalovirus (CMV) and tuberculosis (TB) could help them survive. Over 500 babies aged 1 month to 1 year were randomly assigned to receive either standard care or additional drugs for CMV and TB. The main goal was to see if this approach reduced deaths within 15 days and up to one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Valganciclovir and tuberculosis drugs
What this could lead to
If successful, this approach could reduce deaths in HIV-positive infants with severe pneumonia by treating hidden CMV and TB infections early.
What could go wrong
This is a completed Phase 2/3 trial, but results may not apply to all settings. The drugs have side effects, and the benefit may be limited to specific populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cemtro de Investigaçao em Saúde da Manhiça
Manhiça, Mozambique
-
Fundación para la Investigación Biomédica del Hospital 12 de Octubre
Madrid, 28041, Spain
-
Hospital Central Maputo
Maputo, Mozambique
-
INSERM
Toulouse, France
-
Lusaka Teaching Hospital
Lusaka, Zambia
-
Makerere University - Mulago Hospital
Kampala, Uganda
-
Malawi Liverpool Welcome Trust. Queen Elizabeth Central Hospital College of Medicine
Blantyre, Malawi
-
PENTA Foundation
Padova, Italy
-
Programme PACCI. Centre Hospitalier Cocody.
Abidjan, Côte d’Ivoire
-
Stichting Katholieke Universiteit Radboudumc
Nijmegen, Netherlands
-
University of Lincoln
Lincoln, United Kingdom
-
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
-
Université de Bourdeaux
Bourdeaux, France